+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06925321

Evaluating Fosmanogepix Versus Standard Therapy in Adults With Invasive Mold Infections Caused by Resistant Fungi

Led by Basilea Pharmaceutica · Updated on 2026-10-28

234

Participants Needed

90

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of fosmanogepix, given either intravenously or orally, for treating adults diagnosed with invasive mold infections. This Phase 3 study focuses on patients infected with molds such as Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug-resistant molds. The goal is to compare the all-cause mortality rate by Day 42 after treatment begins. Participants will be assigned to one of two groups Cohort A includes patients receiving either fosmanogepix or the best available standard antifungal therapy, while Cohort B includes patients who did not respond to previous treatments and will receive fosmanogepix only. Fosmanogepix is administered as an intravenous infusion or oral tablet. The study treatment duration is targeted at 84 days but may be extended up to 180 days, followed by a follow-up period. During the study, participants will undergo various assessments including monitoring of mortality rates, treatment responses clinical, mycological, and radiological, and safety evaluations for adverse events and laboratory abnormalities up to approximately 8 months. Blood samples will be collected at specified timepoints to measure drug concentrations. Electrocardiograms and neurological exams will also be conducted during follow-up to monitor safety and treatment effects.

CONDITIONS

Brief Title

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

Research Team

A

Alison Kuchta, MD

M

Marc Engelhardt, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here